ORPHAN MEDICAL, INC., FORM 8-K DATED MAY 19, 2004

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


_____________________________



FORM 8-K



CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934



Date of Report (Date of earliest event reported): May 19, 2004



ORPHAN MEDICAL, INC.

(Exact name of registrant as specified in its charter)



Delaware

0-24760

41-1784594

(State or other jurisdiction of incorporation)

(Commission file number)

(I.R.S. employer identification number)



Suite 250,

13911 Ridgedale Drive,

Minnetonka, MN



55305



(952) 513-6900

(Address of principal executive offices)

(zip code)

(Registrant's telephone number,

 including area code)



Not Applicable

(Former name or former address, if changed since last report)







Item 5.          Other Events.

On May 19, 2004, the Company announced the initial results of a Phase III(b) clinical trial regarding its Xyrem® (sodium oxybate) oral solution product.





















SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 19, 2004. ORPHAN MEDICAL, INC.
 
 
/s/ Timothy G. McGrath
Timothy G. McGrath
Chief Financial Officer
(duly authorized officer and
principal financial officer)


















EXHIBIT INDEX


Exhibit
Number		 Description
 
99.1 Press release dated May 19, 2004.